However, clinical experience with Ruxolitinib, the JAK1/2 inhibitor with the longest clinical history in patients with MF, indicates that these drugs effectively ameliorate the symptoms of MF and specifically reduce splenomegaly but do not halt the progression of the disease to its eventual fatal outcome [4,5,6]. Here, JAK1 is linked to Splenomegaly.